Newsfeeds - Spark Newswire

3 minute read

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate To Be Evaluated In NIH-Sponsored Phase 3 Clinical Trial Of Hyperimmune Intravenous Immunoglobulin For Outpatient Treatment Of COVID-19

Today, 9:23 PM

NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergent's COVID-19 Human Immune Globulin (COVID-HIG), for potential treatment of

EBS

1 minute read

News

Emergent Biosolutions Says Expects To Begin Late Stage Study In Partnership With U.S. Government Of COVID-19 Therapy Candidate In Near Term

By Michael Horton

Today, 9:23 PM

-Reuters Citing Conference Call

EBS

1 minute read

Emergent BioSolutions Q2 EPS $0.33 Down From $1.98 YoY, Sales $397.50M Miss $398.93M Estimate

By Benzinga Newsdesk

Today, 9:23 PM

Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.33 per share. This is a 83.33 percent decrease over earnings of $1.98 per share from the same period last year. The company reported quarterly sales of

EBS

22 minute read

Earnings Scheduled For July 29, 2021

By Benzinga Insights

Today, 9:23 PM

Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.

5 minute read

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More

By Shanthi Rexaline

Today, 9:23 PM

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.

ABBV

1 minute read

These Companies Have Seen Large Returns From 2020 Government Investment

By Sam Corey

Today, 9:23 PM

Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal government.

AJRD

1 minute read

FDA Releases More JNJ’s COVID-19 Vaccine Substance From Baltimore Plant

By Vandana Singh

Today, 9:23 PM

Federal regulators on Friday cleared another batch of the main ingredient for Johnson & Johnson’s (NYSE:JNJ) COVID-19 vaccine, made at Emergent BioSolutions Inc’s (NYSE:EBS)…

EBS